Buprenorphine-induced changes in mu-opioid receptor availability in male heroin-dependent volunteers: A preliminary study

Neuropsychopharmacology

Volumn 23, Issue 3, 2000, Pages 326-334

  Zubieta, Jon Kar ^b   Greenwald, Mark K ^d   Lombardi, Umberto ^b   Woods, James H ^c   Kilbourn, Michael R ^a,b   Jewett, Douglas M ^a,b   Koeppe, Robert A ^a   Schuster, Charles R ^d   Johanson, Chris Ellyn ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

Buprenorphine; Carfentanil; Mu opioid receptors; Opiate dependence; Opiates; Positron emission tomography

Indexed keywords

BUPRENORPHINE; CARBON 11; CARFENTANIL; MU OPIATE RECEPTOR; PLACEBO;

ADULT; ARTICLE; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DETOXIFICATION; DRUG RECEPTOR BINDING; FRONTAL CORTEX; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANALGESICS, OPIOID; BRAIN; BRAIN CHEMISTRY; BUPRENORPHINE; DOUBLE-BLIND METHOD; FENTANYL; HEROIN DEPENDENCE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NARCOTICS; RECEPTORS, OPIOID, MU; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0005840846     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00110-X     Document Type: Article

References (35)

1. Belcheva M.M., Barg J., McHale R.J., Dawn S., Ho M.T., Ignatova E., Coscia C.J. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine. Mol Pharmacol. 44:1993;173-179.
2. Bickel W.K., Amass L. Buprenorphine treatment of opioid dependence. A review Exp Clin Psychopharmacol. 3:1995;477-489.
3. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. Buprenorphine. Dose-related blockade of opioid challenge effects in opioid dependent humans J Pharmacol Exp Ther. 247:1988;47-53.
4. Bolger G.T., Skolnick P., Rice K.C., Weissman B.A. Differential regulation of mu-opiate receptors in heroin- and morphine-dependent rats. FEBS Lett. 234:1988;22-26.
5. 18F]cyclofoxy and positron emission tomography J Cereb Blood Flow Metab. 13:1993;24-42.
6. Cowan A., Lewis J.W., Macfarlane I.R. Agonist and antagonist properties of buprenorphine. A new antinociceptive agent Br J Pharmacol. 60:1977;537-545.
7. Dannals R.F., Ravert H.T., Frost J.J., Wilson A.A., Burns H.D., Wagner H.N. Jr. Radiosynthesis of an opiate receptor binding radiotracer. [11C]carfentanil Int J Appl Radiat Isot. 36:1985;303-306.
8. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis Disorders - Patient Edition (SCID-I/P, Version 2.0). 1996;NY: Biometrics Research Dept., NY State Psychiatric Institute, New York.
9. 11C]carfentanil binding to opiate receptors in humans measured by positron emission tomography. J Cereb Blood Flow Metab. 9:1989;398-409.
10. Greenwald M.K., Johanson C.E., Schuster C.R. Opioid reinforcement in heroin-dependent volunteers during buprenorphine maintenance. Drug Alcohol Depend. 56:1999;191-203.
11. Heel R.C., Brogdon R.N., Speight T.M., Avery G.S. Buprenorphine. a review of its pharmacological properties and therapeutic efficacy Drugs. 17:1979;81-110.
12. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 40:1995;17-25.
13. 18F]cyclofoxy. NIDA Res Monogr. 174:1997;120.
14. Koeppe R.A. Data analysis for PET studies of neuroreceptor modulation. J Nucl Med. 5:1999;287P.
15. Kristensen K., Christensen C.B., Christrup L.L. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci. 56:1995;PL45-PL50.
16. Lange W.R., Fudala P.J., Dax E.M., Johnson R.E. Safety and side effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. 26:1990;19-28.
17. Lewis J.W., Rance M.J., Sanger D.J. The pharmacology and abuse potential of buprenorphine. A new antagonist analgesic Mello N.K. Advances in Substance Abuse, Vol. 3. 1983;103-154 JAI Press, Greenwich, CT.
18. Logan J., Fowlr J.S., Volkow N.D., Wang G.-J., Ding Y.-S., Alexoff D.L. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 16:1996;834-840.
19. McLellan A.T., Luborsky L., Cacciola J., Griffith J., Evans F., Barr H.L., O'Brien C.P. New data from the Addiction Severity Index. J Nerv Ment Dis. 173:1985;412-423. a.
20. McLellan A.T., Luborsky L., O'Brien C.P. Improved diagnostic instrument for substance abuse patients. The Addiction Severity Index J Nerv Ment Dis. 168:1985;26-33. b.
21. Mello N.K., Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science. 207:1980;657-659.
22. Mello N.K., Mendelson J.H., Kuehnle J.C. Buprenorphine effects on human heroin self-administration. An operant analysis J Pharmacol Exp Ther. 223:1982;30-39.
23. Mello N.K., Mendelson J.H., Kuehnle J.C., Sellers M.S. Operant analysis of human heroin self-administration. J Pharmacol Exp Ther. 216:1981;45-54.
24. Minoshima S., Berger K.L., Lee K.S., Mintun M.A. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med. 33:1992;1579-1585.
25. Minoshima S., Koeppe R.A., Mintun M.A., Berger K.L., Taylor S.F., Frey K.A., Kuhl D.E. Automated detection of the intercommisural line for stereotactic localization of functional brain images. J Nucl Med. 34:1993;322-329.
26. Minoshima S., Koeppe R.A., Frey K.A., Kuhl D.E. Anatomic standardization. linear scaling and nonlinear warping of functional brain images J Nucl Med. 35:1994;1528-1537.
27. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol. 15:1984;217-227.
28. Rosen M.I., Wallace E.A., McMahon T.J., Pearsall H.R., Woods S.W., Price L.H., Kosten T.R. Buprenorphine. Duration of blockade of effects of intramuscular hydromorphone Drug Alcohol Depend. 35:1994;141-149.
29. Schottenfeld R.S., Pakes J., Ziedonis D., Kosten T.R. Buprenorphine. Dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans Biol Psychiatry. 34:1993;66-74.
30. Schuster C.R., Greenwald K., Johanson C.E., Heishman S.J. Measurement of drug craving during naloxone-precipitated withdrawal in methadone maintained volunteers. Exp Clin Psychopharmacol. 3:1995;424-431.
31. Talairach J., Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. 1988;Georg Thieme Verlag, New York.
32. Tempel A., Habas J., Paredes W., Barr G.A. Morphine-induced downregulation of mu-opioid receptors in neonatal rat brain. Brain Res. 469:1988;129-133.
33. Ulibarri I., Garcia-Sevilla J.A., Ugedo L. Modulation of brain alpha 2-adrenoceptor and mu-opioid receptor densities during morphine dependence and spontaneous withdrawal in rats. Naunyn-Schmied Arch Pharmacol. 336:1987;530-537.
34. Zubieta J.K., Dannals R.F., Frost J.J. Gender and age influences on human brain mu opioid receptor binding measured by PET. Am J Psychiatry. 156:1999;842-848.
35. Zubieta J.K., Gorelick D.A., Stauffer R., Ravert H.T., Dannals R.F., Frost J.J. Increased mu opioid receptor availability in cocaine abuse and its association with cocaine craving. Nature Med. 2:1996;1225-1229.